Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 20 April 2009, doi:10.1136/bmj.b1627
Cite this as: BMJ 2009;338:b1627
Peter Moszynski
1 London
| The first 150 words of the full text of this article appear below. |
Fighting malaria is part of the United Nations sixth millennium development goal, yet a new generation of frontline drugs remains out of reach of most patients, so a new £150m (
170m; $220m) scheme has been developed to subsidise their cost.
Launched last week in Oslo, the Affordable Medicines Facility for Malaria is an innovative financing mechanism designed to expand access to artemisinin based combination drugs, the most effective treatment.
In 2006 about 250 million people developed malaria, of whom nearly a million died. Malaria parasites are becoming increasingly resistant to older drugs, such as chloroquine and pyrimethamine with sulfadoxine, which are still often used because they are relatively cheap.
"The age when the world had effective drugs against infectious diseases but let millions die each year because they couldnt afford them is over," said Norways foreign minister, Jonas Gahr Støre, at the launch.
He said, "Thanks to new commitments,
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses